Astrazeneca (AZN) Common Equity (2009 - 2026)

Astrazeneca has reported Common Equity for 18 years, with the latest figure at $50.4 billion in Q2 2026.

• On a quarterly basis, Common Equity rose 12.41% year-over-year to $50.4 billion in Q2 2026; TTM through Jun 2026 was $50.4 billion, a 12.41% increase from a year earlier, with the FY2025 full-year figure at $48.7 billion, up 19.2% from the prior year.
• Common Equity was $50.4 billion for Q2 2026 at Astrazeneca, up from $47.4 billion in the prior quarter.
• The five-year high for Common Equity was $50.4 billion in Q2 2026, with the low at $35.2 billion in Q3 2022.
• Average Common Equity over 5 years is $40.6 billion, with a median of $39.4 billion recorded in 2023.
• The largest YoY upside for Common Equity was 151.69% in 2022 against a maximum downside of 11.92% in 2022.
• Over 5 years, Common Equity stood at $37.1 billion in 2022, then rose by 5.69% to $39.2 billion in 2023, then grew by 4.35% to $40.9 billion in 2024, then gained by 19.2% to $48.7 billion in 2025, then advanced by 3.39% to $50.4 billion in 2026.
• The last three Common Equity figures came in at $50.4 billion (Q2 2026), $47.4 billion (Q1 2026), and $48.7 billion (Q4 2025), per Business Quant data.